Your browser doesn't support javascript.
loading
Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples.
Sherwood, Alexander M; Kargbo, Robert B; Kaylo, Kristi W; Cozzi, Nicholas V; Meisenheimer, Poncho; Kaduk, James A.
Afiliação
  • Sherwood AM; Usona Institute, 2780 Woods Hollow Rd, Madison, WI 53711, USA.
  • Kargbo RB; Usona Institute, 2780 Woods Hollow Rd, Madison, WI 53711, USA.
  • Kaylo KW; Usona Institute, 2780 Woods Hollow Rd, Madison, WI 53711, USA.
  • Cozzi NV; Neuropharmacology Laboratory, University of Wisconsin, School of Medicine and Public Health, 1300 University Avenue, Madison, WI 53706, USA.
  • Meisenheimer P; Usona Institute, 2780 Woods Hollow Rd, Madison, WI 53711, USA.
  • Kaduk JA; Department of Physics, North Central College, 131 S Loomis Street, Naperville, IL 60540, USA.
Acta Crystallogr C Struct Chem ; 78(Pt 1): 36-55, 2022 01 01.
Article em En | MEDLINE | ID: mdl-34982048
ABSTRACT
Psilocybin {systematic name 3-[2-(dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate} is a zwitterionic tryptamine natural product found in numerous species of fungi known for their psychoactive properties. Following its structural elucidation and chemical synthesis in 1959, purified synthetic psilocybin has been evaluated in clinical trials and has shown promise in the treatment of various mental health disorders. In a recent process-scale crystallization investigation, three crystalline forms of psilocybin were repeatedly observed Hydrate A, Polymorph A, and Polymorph B. The crystal structure for Hydrate A was solved previously by single-crystal X-ray diffraction. This article presents new crystal structure solutions for the two anhydrates, Polymorphs A and B, based on Rietveld refinement using laboratory and synchrotron X-ray diffraction data, and density functional theory (DFT) calculations. Utilizing the three solved structures, an investigation was conducted via Rietveld method (RM) based quantitative phase analysis (QPA) to estimate the contribution of the three different forms in powder X-ray diffraction (PXRD) patterns provided by different sources of bulk psilocybin produced between 1963 and 2021. Over the last 57 years, each of these samples quantitatively reflect one or more of the hydrate and anhydrate polymorphs. In addition to quantitatively evaluating the composition of each sample, this article evaluates correlations between the crystal forms present, corresponding process methods, sample age, and storage conditions. Furthermore, revision is recommended on characterizations in recently granted patents that include descriptions of crystalline psilocybin inappropriately reported as a single-phase `isostructural variant.' Rietveld refinement demonstrated that the claimed material was composed of approximately 81% Polymorph A and 19% Polymorph B, both of which have been identified in historical samples. In this article, we show conclusively that all published data can be explained in terms of three well-defined forms of psilocybin and that no additional forms are needed to explain the diffraction patterns.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psilocibina Tipo de estudo: Prognostic_studies Idioma: En Revista: Acta Crystallogr C Struct Chem Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psilocibina Tipo de estudo: Prognostic_studies Idioma: En Revista: Acta Crystallogr C Struct Chem Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos